Status:
COMPLETED
"Can Soluble-CD163 Discriminate Between Healthy and Unhealthy Obese Individuals?"
Lead Sponsor:
University of Aarhus
Collaborating Sponsors:
Novo Nordisk A/S
The Danish Medical Research Council
Conditions:
Obesity
Insulin Resistance
Eligibility:
All Genders
30-60 years
Brief Summary
CD163 is a membrane bound receptor primary expressed in monocytes and macrophages. A soluble variant of CD163 (sCD163) is present in plasma and is elevated in pathological condition activating the mon...
Detailed Description
It is recognized that low grade inflammation is a key player in the development of atherosclerosis and insulin resistance (Haslam, James 2005). Circulating levels of inflammatory markers such as high ...
Eligibility Criteria
Inclusion
- Male/Female
- Legally competent (Habil)
- Age 30-60
- Approved to gastric bypass, according to current criteria in Denmark
- Written consent
- Investigators verification of the suitability
Exclusion
- Heart, liver or kidney disease
- Treatment with cortisol
- MR-contraindications
- Abuse/addiction
- Malignancy
- Weight more than 145 kg because of problems with DXA and MRI
Key Trial Info
Start Date :
November 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2014
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT01463449
Start Date
November 1 2011
End Date
August 1 2014
Last Update
August 13 2014
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Endocrinology, Aarhus University Hospital
Aarhus, Denmark, 8000
2
Department of Endocrinology, Aarhus University Hospital
Aarhus C, Denmark, 8000